Mitoxantrone and VP-16,213 (MVP16) in AML Patients Refractory to Cytosine Arabinoside with Daunorubicin and High-Dose Cytosine Arabinoside with Amsidine: Preliminary Results

Simon Daenen; Bob Löwenberg; Pieter Sonneveld; G. Verhoeff; R. Huygen; Leo F. Verdonck; L. Verdonck

doi:10.1007/978-3-642-76591-9_73

ScienceGate Book Chapters

BOOK-CHAPTER

Mitoxantrone and VP-16,213 (MVP16) in AML Patients Refractory to Cytosine Arabinoside with Daunorubicin and High-Dose Cytosine Arabinoside with Amsidine: Preliminary Results

Simon Daenen Bob Löwenberg Pieter Sonneveld G. Verhoeff R. Huygen Leo F. Verdonck L. Verdonck

Year: 1992 Hämatologie und Bluttransfusion Pages: 437-438 Publisher: Springer Nature

DOI: 10.1007/978-3-642-76591-9_73

Get Full-Text PDF Get Analytical Report

Keywords:

Mitoxantrone Daunorubicin Cytosine Refractory (planetary science) Amsacrine Cytarabine Medicine Myeloid leukemia Internal medicine Leukemia Chemotherapy Pharmacology Oncology Gastroenterology Chemistry Biology Etoposide Biochemistry

Metrics

Cited By

2.24

FWCI (Field Weighted Citation Impact)

Refs

0.72

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Topics

Acute Myeloid Leukemia Research

Health Sciences → Medicine → Hematology

Neutropenia and Cancer Infections

Health Sciences → Medicine → Oncology

Acute Lymphoblastic Leukemia research

Health Sciences → Medicine → Public Health, Environmental and Occupational Health

Mitoxantrone and VP-16,213 (MVP16) in AML Patients Refractory to Cytosine Arabinoside with Daunorubicin and High-Dose Cytosine Arabinoside with Amsidine: Preliminary Results

Metrics

Topics

Related Documents

Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia

High-dose cytosine arabinoside

High dose cytosine arabinoside

Mitoxantrone, Cytosine Arabinoside, and VP-16 in 36 Patients with Relapsed and Refractory Acute Myeloid Leukemia

High-dose cytosine arabinoside therapy for refractory leukemia